Thermo Fisher Scientific (NYSE:TMO – Get Free Report) and Champions Oncology (NASDAQ:CSBR – Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, profitability, valuation, analyst recommendations, dividends and institutional ownership.
Profitability
This table compares Thermo Fisher Scientific and Champions Oncology’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Thermo Fisher Scientific | 15.04% | 17.09% | 8.12% |
| Champions Oncology | -1.87% | -27.48% | -3.84% |
Valuation and Earnings
This table compares Thermo Fisher Scientific and Champions Oncology”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Thermo Fisher Scientific | $44.56 billion | 5.27 | $6.70 billion | $18.59 | 34.13 |
| Champions Oncology | $59.42 million | 1.15 | -$1.17 million | ($0.08) | -61.50 |
Thermo Fisher Scientific has higher revenue and earnings than Champions Oncology. Champions Oncology is trading at a lower price-to-earnings ratio than Thermo Fisher Scientific, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Thermo Fisher Scientific has a beta of 0.85, meaning that its stock price is 15% less volatile than the S&P 500. Comparatively, Champions Oncology has a beta of 0.4, meaning that its stock price is 60% less volatile than the S&P 500.
Analyst Ratings
This is a summary of current recommendations for Thermo Fisher Scientific and Champions Oncology, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Thermo Fisher Scientific | 0 | 6 | 16 | 1 | 2.78 |
| Champions Oncology | 1 | 0 | 0 | 0 | 1.00 |
Thermo Fisher Scientific presently has a consensus target price of $619.41, suggesting a potential downside of 2.38%. Given Thermo Fisher Scientific’s stronger consensus rating and higher possible upside, analysts plainly believe Thermo Fisher Scientific is more favorable than Champions Oncology.
Insider & Institutional Ownership
89.2% of Thermo Fisher Scientific shares are held by institutional investors. Comparatively, 41.3% of Champions Oncology shares are held by institutional investors. 0.3% of Thermo Fisher Scientific shares are held by insiders. Comparatively, 47.0% of Champions Oncology shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
Thermo Fisher Scientific beats Champions Oncology on 14 of the 15 factors compared between the two stocks.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
About Champions Oncology
Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
